Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Monday

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) will likely be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of ($0.9133) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.28. On average, analysts expect Cadrenal Therapeutics to post ($3.86) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Cadrenal Therapeutics Stock Down 2.0%

Shares of NASDAQ:CVKD opened at $0.98 on Friday. Cadrenal Therapeutics has a 12 month low of $0.82 and a 12 month high of $13.01. The company’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $3.79. The firm has a market cap of $3.50 million, a P/E ratio of -0.20 and a beta of 1.94.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.00.

Get Our Latest Analysis on Cadrenal Therapeutics

About Cadrenal Therapeutics

(Get Free Report)

Cadrenal Therapeutics, Inc (NASDAQ: CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant designed for individuals with implanted mechanical heart valves and other mechanical circulatory support devices.

Tecarfarin is a vitamin K antagonist intended to address challenges associated with existing anticoagulant therapy, including drug interactions and changes in a patient’s metabolism.

Featured Stories

Earnings History for Cadrenal Therapeutics (NASDAQ:CVKD)

Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.